Inflammation

Apellis Pharmaceuticals has identified internal structural variations in the 19-gauge filter needle included in certain Syfovre injection kits as part of its investigation into the recent reports of retinal vasculitis.

Healio’s top ophthalmology items so far in August include the FDA approval of Izervay for geographic atrophy and phase 3 results of OCS-01 eye drops for the treatment of inflammation and pain after cataract surgery.

Eyenovia has acquired the exclusive U.S. rights to distribute and sell APP13007, a potential treatment for inflammation and pain after ocular surgery, under an agreement with Formosa Pharmaceuticals, according to a press release.

Healio’s recent coverage of the American Society of Retina Specialists annual meeting included a study about the burden of geographic atrophy and updates on Syfovre inflammation reports.

New serum proteomic analyses suggest that a distinct dysregulation of inflammatory and cholesterol-related pathways drive peripartum cardiomyopathy, a rare but serious complication of pregnancy occurring more frequently among Black women.

OCS-01 eye drops demonstrated positive topline results for the treatment of inflammation and pain after cataract surgery, according to a press release from Oculis.

SEATTLE — Apellis Pharmaceuticals reported there is no indication that drug product or manufacturing issues contributed to recent reports of retinal vasculitis linked with Syfovre.

Among patients with ulcerative colitis, delayed Stelara responders had greater inflammatory burden at baseline compared with early responders, yet similar 1-year clinical remission outcomes, researchers reported.

The advancement of retinal therapies offers promise and hopefully no peril to those willing to push the boundaries of medical science into new indications.

Children and young adults who have longer sedentary time are more likely to have high C-reactive protein levels, an indicator of greater inflammation, according to study findings.